Stoic VC

First-in-Class, Broad-Spectrum Nasal Spray to Prevent COVID-19 and Other Common Respiratory Illnesses Set to Begin Phase 2 Trials

-- ENA Respiratory engages PPD, Inc. for Phase 2 COVID-19 post-exposure prophylaxis study and hVIVO for influenza challenge study to assess the efficacy of fast-acting nasal spray designed to boost innate immunity SYDNEY, Australia, Sept. 28,…
Stoic VC

Certa Therapeutics announces new clinical trial of investigative candidate

One of our Stoic VC life-science investee companies Certa Theraputics is advancing to Phase 2 trial in treating Diffuse Systemic Scleroderma, a debilitating chronic autoimmune disease. Certa Therapeutics has announced the launch of a Phase 2…
Stoic VC

Survive the journey: PERKii sees steady sales of probiotic drinks made with exclusive encapsulation technology

Australian probiotic brand PERKII has seen steady sales of its probiotic beverages amid the pandemic, boosting the firm’s confidence in its overseas expansion plans. HTTPS://WWW.BEVERAGEDAILY.COM/ARTICLE/2021/09/01/SURVIVE-THE-JOURNEY-PER…
Stoic VC